Abstract
Ovarian clear cell carcinomas (OCCC) are rare aggressive, chemo-resistant tumours comprising approximately 13% of all epithelial ovarian cancers, which have distinct clinical and molecular features, when compared to other gynaecological malignancies. At present, there are no specific licensed targeted therapies for OCCC, although a number of candidate targets have been identified. This review focuses on recent knowledge underpinning our understanding of the pathogenesis of OCCC including direct and synthetic-lethal therapeutic strategies in particular focussing on ARID1A deficiency. We also discuss current targeted clinical trials and immunotherapeutic approaches.
Keywords:
ARID1A; Endometriosis; Immunotherapy; Ovarian clear cell; Targeted therapies.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adenocarcinoma, Clear Cell / diagnosis
-
Adenocarcinoma, Clear Cell / etiology*
-
Adenocarcinoma, Clear Cell / metabolism
-
Adenocarcinoma, Clear Cell / therapy
-
Biomarkers
-
Carcinoma, Ovarian Epithelial / diagnosis
-
Carcinoma, Ovarian Epithelial / etiology*
-
Carcinoma, Ovarian Epithelial / metabolism
-
Carcinoma, Ovarian Epithelial / therapy
-
DNA Copy Number Variations
-
DNA-Binding Proteins / genetics
-
Disease Management
-
Epigenesis, Genetic
-
Female
-
Genetic Association Studies
-
Genetic Predisposition to Disease
-
Genomics* / methods
-
Humans
-
Mutation
-
Neovascularization, Pathologic / drug therapy
-
Neovascularization, Pathologic / genetics
-
Neovascularization, Pathologic / metabolism
-
Signal Transduction
-
Transcription Factors / genetics
-
Translational Research, Biomedical*
Substances
-
ARID1A protein, human
-
Biomarkers
-
DNA-Binding Proteins
-
Transcription Factors